Editas Medicine Inc.
- BID
2.52
- ASK
2.54
- 23,809 Units3,937 Units
- 07/21, 21:31:20 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
6.00%
Market Cap
441.41 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-1.60 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 2.52 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:31:06 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 2.57 | 2.46 |
| PREV. DAY'S PRICE | 2.51 | (07/20) |
| CHANGE DAY BEFORE | +0.01 | 0.40 % |
| 52 WEEK HIGH / LOW | 3.555 (10/20) | 1.3635 (02/06) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.87 | -2.66 | -1.60 | -0.91 | -0.89 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 2.37 | 0.78 | 7.35 | - | - |
PRICE - SALES RATIO | 9.85 | 3.24 | 4.49 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2AC4K |
| ISIN | US28106W1036 |
| SYMBOL | 8EM |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | EDITAS MEDICINE DL-,0001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 81.81 Mil. |
| MARKET CAPITALISATION | 441.41 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -8.39 % | 9.13 % | -17.70 % | 45.89 % | 6.00 % | -67.78 % | -93.45 % | 46.27 % |
| HIGH | 2.78 | 3.33 | 3.33 | 3.33 | 3.56 | 10.14 | 60.66 | 3.33 |
| LOW | 2.42 | 2.30 | 1.94 | 1.36 | 1.36 | 0.83 | 0.83 | 1.36 |
Dividende
pro Aktie
EDITAS MEDICINE DL-,0001 does not deliver dividend information
Company profile
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
Structured products for Editas Medicine Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.